




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61F 2/06</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/15105</b>
			(43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: <b>PCT/IB98/01459</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 September 1998 (21.09.98)			
(30) Priority Data:			
08/935,784	23 September 1997 (23.09.97)	US	
09/005,972	12 January 1998 (12.01.98)	US	
09/035,114	4 March 1998 (04.03.98)	US	
09/053,200	1 April 1998 (01.04.98)	US	
09/156,034	17 September 1998 (17.09.98)	US	
(71)(72) Applicant and Inventor: VONDERWALDE FREIDBERG, Carlos [MX/MX]; San Luis Potosi 96, Colonia Roma, Mexico, D.F. 06700 (MX).		Published With international search report.	

(54) Title: NON-THROMBOGENIC STENT JACKET



## (57) Abstract

A jacketed stent assembly comprising a tubular, expandable stent, preferably having a metallic framework, jacketed with a cylinder of biocompatible, non-thrombogenic expandable material, such as heterologous tissue, which, in a preferred embodiment, contains a therapeutic or diagnostic agent. In a preferred embodiment, the jacket of the expandable stent is formed of bovine or porcine pericardial tissue. A delivery catheter having an expandable member on its distal extremity may be used to deliver the stent assembly to a desired region in a lumen of a patient. The jacketed stent is expanded to be seated within the body lumen. Self-expanding jacketed stents are also contemplated.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**NON-THROMBOGENIC STENT JACKET****RELATED APPLICATIONS**

This application is a continuation-in-part application of application Serial No. 08/935,784, filed September 23, 1997, entitled STENT COVERED WITH  
5 HETEROLOGOUS TISSUE, and application Serial No. 09/005,972, filed January 12, 1998, entitled STENT WITH A BIOCOMPATIBLE NON-THROMBOGENIC JACKET, and application Serial No. 09/035,114, filed March 4, 1998, entitled NON-THROMBOGENIC STENT JACKET CONTAINING THERAPEUTIC AGENTS, and application Serial No. 09/053,200, filed April 1, 1998, entitled NON-  
10 THROMBOGENIC STENT JACKET, which are incorporated herein in their entirety.

**BACKGROUND OF THE INVENTION**

This invention relates to the field of expandable intraluminal support devices such as stents and the like. Typically, stents are expandable, tubular  
15 metallic devices that are positioned within a patient's vasculature or other body lumen and expanded in order to support a vessel or body lumen at a desired intraluminal location to allow the flow of blood or other body fluids therethrough. Often, the stents are formed from a deformable metal and delivered to the desired intraluminal location by mounting the stent onto an expandable portion,  
20 e.g. a balloon, on the distal extremity of a delivery catheter. By advancing the catheter through the body lumen, the stent may be delivered to a desired position and expanded therein by expanding the expandable member, e.g. the balloon to an expanded configuration, seating it within the artery or other body lumen. Other implementations make use of a self-expanding stent formed from  
25 a suitable material such as pseudoelastic material that is delivered in a constricted condition and when released spontaneously expands to an enlarged configuration. In other embodiments, a stent made of shape memory alloy (e.g. NiTi alloy) may be inserted into the body lumen in a martensitic phase and transformed to an austenite phase which has an expanded memory when raised  
30 to a temperature above the transformation temperature, usually less than 45°C.

Stents are often used in conjunction with an intravascular treatment for obstructive coronary artery disease. For example, ablation, atherectomy, balloon dilation, laser treatment or other procedures are among the methods used to widen a stenotic region of a patient's vasculature. However, restenosis occurs in large percentage of percutaneous transluminal coronary angioplasty (PTCA) patients and rates can be even higher with other procedures. The prior art has employed a number of mechanical and pharmacological strategies to reduce the restenosis rate, but none have been particularly effective. Accordingly, stents have been proposed to maintain the patency of a treated vessel and prevent restenosis. Using stents, restenosis rates have fallen to less than 20%.

Restenosis is thought to be a natural healing reaction provoked by injury from the intravascular procedure. The healing process frequently causes thrombosis and may lead to intimal hyperplasia that occludes the vessel. Although helpful in reducing restenosis, stents do not represent a complete solution. The framework of the stent may still allow migration and proliferation of the smooth muscle cells, while the stent itself can be thrombogenic. To address these problems, stents have been covered with DACRON, PTFE and autologous vein and the stent surface has been seeded with endothelial cells or otherwise treated. Each of these solutions suffer from certain drawbacks, such as not being biocompatible, lacking sufficient mechanical strength, having a surface that is difficult to prepare, lack of ready availability and being thrombogenic. Antithrombotic drug regimens, in which anticoagulants and thrombolytic agents are administered during and after deployment of the stent, have also been employed to reduce the risk of thrombosis.

Thus, there remains a need for a stent capable of minimizing restenosis while having a consistency similar to the native artery, a non-thrombogenic surface and sufficient mechanical strength as well as being biocompatible and readily available. This invention satisfies these and other needs.

### **SUMMARY OF THE INVENTION**

The invention is directed to a stent assembly suitable for maintaining the patency of a bodily lumen, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue

disposed about the exterior of the expandable stent. Preferably, the heterologous tissue is selected from the group consisting of bovine pericardium, porcine pericardium, aortic leaflet and other suitable heterologous tissue. The stent may be an expandable, tubular framework and may be a conventional self  
5 expanding or balloon expandable stent. The jacket is disposed about either or both of the outer and inner surfaces of the stent. In a preferred embodiment, the jacket is generally cylindrical for corresponding to the tubular framework or the stent.

This invention is also directed to a method for maintaining the patency of  
10 a bodily lumen generally comprising providing a delivery catheter having an expandable member on the distal extremity thereof, mounting the stent assembly, including a tubular stent with a jacket of biocompatible, non-thrombogenic expandable material such as heterologous tissue disposed about at least part of the stent, on the expandable member on the distal extremity of the  
15 delivery catheter. The catheter is advanced through the body lumen within the patient until the distal extremity of the catheter having the stent assembly is positioned at a desired location therein. The stent assembly is expanded by expanding the expandable member onto which the stent assembly is mounted to anchor the stent assembly within the body lumen. Once the stent assembly is  
20 effectively positioned within the body lumen, the expanded expandable member may be contracted, e.g. by deflating the balloon, and then the delivery catheter may be withdrawn.

A presently preferred embodiment of the invention is directed to a stent assembly suitable for expansion within a body lumen and delivery of a  
25 therapeutic or diagnostic agent therein, generally comprising an expandable stent and an expandable, biocompatible, non-thrombogenic jacket such as heterologous tissue, which contains the therapeutic or diagnostic agent and which is disposed about the expandable stent. The jacket releasably contains at least one therapeutic or diagnostic agent.

30 A wide variety of therapeutic or diagnostic agents for a variety of indications can be used, including angiogenesis agents and antithrombotic agents. The term "antithrombotic agents" is meant to include various agents for

reducing the risk of thrombosis, including anticoagulants such as heparin, thrombolytic agents such as urokinase, streptokinase, tissue plasminogen activator (ACTILYSE), monoclonal antibodies such as abciximab (REOPRO), fibrinolytic agents, and the like. Angiogenesis agents that stimulate the growth of neo-vessels include agents such as basic Fibroblast Growth Factor (bFGF) and Vascular Endothelial Growth Factor (VEGF).

In a presently preferred embodiment, the jacket is impregnated with a liquid containing the therapeutic or diagnostic agent. For example, a jacket formed from heterologous tissue which is submerged in a solution of the therapeutic agent will absorb the solution. A variety of suitable methods of applying the agent to the jacket may be used, including using electrodeposition, heat and pressure. Thereafter, the stent assembly can be positioned at a desired site within the patient's body lumen, where the jacket will release the therapeutic agent. The jacket on the stent assembly may be impregnated just before use, or alternatively, stored in the therapeutic or diagnostic agent so that the stent assembly is preimpregnated.

The invention is also directed to a method for delivery of a therapeutic or diagnostic agent within a body lumen. The stent assembly including a tubular stent with a jacket of biocompatible, non-thrombogenic expandable material, such as heterologous tissue, containing a therapeutic or diagnostic agent is positioned within the body lumen as outlined above. With the stent assembly positioned at a desired location, the therapeutic or diagnostic agent is released from the jacket into the body lumen and thereby delivered at and around the location of the stent assembly within the body lumen.

The expanded jacket of biocompatible, non-thrombogenic expandable material such as heterologous tissue should extend over a substantial portion, preferably all, of the stenotic region in which it is disposed in order to minimize the restenosis.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a perspective view, partially broken away, of a stent assembly of the invention showing a tubular, expandable stent with an expandable biocompatible non-thrombogenic cylindrical exterior jacket.

Figure 2 is an elevational view, partially in section, of a delivery catheter having a jacketed stent mounted on an inflatable balloon on the distal extremity of the catheter.

Figure 3 is a transverse cross sectional view of the stent assembly shown in Figure 1, taken along lines 3-3.

Figure 4 is a perspective view, partially in section, of one embodiment of the stent assembly, shown in the expanded configuration, having a biocompatible non-thrombogenic jacket covering the length of the expandable stent.

Figure 5 is a transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non-thrombogenic jacket in a S-shaped folded configuration.

Figure 6 is a transverse cross sectional view of another embodiment of the stent assembly prior to being expanded, illustrating the biocompatible non-thrombogenic jacket in a U-shaped folded configuration.

Figure 7 is a perspective view, partially broken away, of one embodiment of the stent assembly having a biocompatible non-thrombogenic jacket comprising an overlapping ribbon.

Figure 8 is transverse cross sectional view of one embodiment of the stent assembly prior to being expanded, having a biocompatible non-thrombogenic jacket in an overlapping wrapped configuration.

## **DETAILED DESCRIPTION OF THE INVENTION**

In the embodiment of the invention shown in Fig. 1, stent assembly 10 comprises a tubular, expandable metallic framework forming the stent 12 with an exterior jacket 14 of heterologous tissue. In the embodiment illustrated in Figure 1, metallic stent 12 extends about 1 mm beyond each end of jacket 14 to prevent prolapse of the tissue into the lumen of the stent when it is expanded. Jacket 14 may be secured to metallic framework 12 by any suitable means. For

example, four radially spaced sutures 16 may be placed at each end of jacket 14.

In a presently preferred embodiment of the stent assembly illustrated in Fig. 1, the jacket 14 contains a therapeutic or diagnostic agent, as shown in Fig. 3, illustrating a transverse cross section of the stent assembly shown in Fig. 1, taken along lines, 3-3.

Exterior jacket 14 preferably comprises bovine pericardium, a material shown to resist suture line bleeding, require no pre-clotting, support endothelialization and have an excellent host-tissue response. Further, bovine pericardial tissue has an elasticity of up to about 30% which allows the tissue cylinder to conform to both the unexpanded and expanded configurations of the stent 12 without adding a great deal of bulk which increases the profile on the balloon. Other heterologous tissue suitable in the practice of the invention includes porcine pericardium, aortic leaflet, veins and arteries, and others.

Useful heterologous tissue is relatively impervious and impenetrable so as to prevent tissue build up and the migration of smooth muscle cells through the stent framework. A particularly preferred bovine pericardium has cross-linked collagen and is available from Bio Vascular. Bovine pericardium tissue is available in a thickness ranging from about 0.25 mm to about 0.75 mm, with an average of about 0.45 mm.

In a presently preferred embodiment of the invention, the biocompatible non-thrombogenic jacket 14 has a thickness of less than about 0.25 mm, and preferably has a thickness of about 0.05 mm to about 0.20 mm, and most preferably about 0.1 mm to about 0.15 mm. However, biocompatible non-thrombogenic jackets having a thickness of up to about 0.75 mm may be used. In the embodiment of the invention in which a thin biocompatible non-thrombogenic jacket having a thickness of less than about 0.25 mm is used, the heterologous tissue used to form the jacket is typically thinned before being assembled with the stent. The tissue may be thinned by a variety of suitable methods including peeling, shaving or otherwise removing a thin layer of the tissue. In a presently preferred embodiment, the thin jacket comprises the serous pericardium, which is the smooth, inner layer of the pericardium, which



has been separated from at least a part of the outer layer of the pericardium. Similarly, where other forms of heterologous tissue are used, such as veins or arteries, the venous or arterial walls may be thinned to the presently preferred thickness of about 0.05 mm to about 0.20 mm. As a result of being thinned, the jacket may have reduced elasticity, so that the thin jacket is preferably provided on the unexpanded stent in a folded or overlapping wrapped configuration which provides sufficient material to cover the larger circumference of the expanded stent, as will be discussed in greater detail below.

10           The biocompatible non-thrombogenic jacket 14 preferably has a length configured to cover the length of the expanded stent, as illustrated in Fig. 4, showing an expanded stent 12 with a jacket 14 extending the length of the stent, with a length equal to the stent length. However, the jacket may have a length that is not equal to the length of the stent. For example, the jacket may have a length less than the stent length, as illustrated in Fig. 1, preferably not more than about 10%-20% less than the length of the stent. However, the jacket may cover an even smaller percentage of the length of the stent, as for example, when the stent assembly is used in a Transjugular Intrahepatic Portal Shunt (TIPS) application, where the jacket length is about 50% less than the length of the stent. Alternatively, the jacket may have a length greater than the length of the stent, preferably not more than about 5% greater than the stent length. The jacket preferably has a circumference about equal to the circumference of the expanded stent, configured to fit on an inner or outer surface of the expanded stent. The jacket preferably fits on the expanded stent so that the jacket conforms to the expanded stent without flaps of excess material.

          Metallic stent 12 may comprise any suitable conventional stent. For example, Micro Stent II and GFX stents available from Arterial Vascular Engineering, and Multi-Link, available from Guidant, have proven useful. Other stents that may be used in the practice of this invention include the Palmaz-Shatz stent from Johnson and Johnson, the Gianturco stent from Cook Incorporated and other commercially available stents. Conventional balloon

expandable stents are preferred, but, as previously mentioned, self-expanding stents, such as those formed from shape memory materials, are also suitable.

The stent assembly is formed by covering a surface of the unexpanded stent with the heterologous tissue forming the jacket 14. In one embodiment, the heterologous tissue is mounted onto the unexpanded stent in the form of a cylinder of tissue. The cylinder of heterologous tissue forming the jacket 14, may be formed by cutting a rectangle of tissue having a length about 2 mm shorter than the stent on which it is to be mounted and a width about equal to the circumference of the expanded stent. The two sides corresponding to the length of the stent then may be secured together, such as by sewing with 6-0, 7-0, 8-0 or 10-0 polypropylene sutures. Other means for securing the sides of the stent cover together include mechanical means such as staples, adhesive or chemical bonding and the like. It may be desirable to support the tissue while manipulating it. For example, a 9 French introducer dilator may be used to support a 3 mm diameter cylinder, an 11 French dilator for a 3.5 mm cylinder and a 12 French dilator for a 4 mm cylinder. The cylinder of tissue having a circumference about equal to the circumference of the expanded stent may be provided on the unexpanded stent in a folded or wrapped configuration. In one embodiment, the tissue on the unexpanded stent forms wings 30 on either side of the stent which are folded about stent, reducing the profile of the assembly, and unfolding upon expansion of the stent. In the embodiment illustrated in Fig. 5, the wings are folded in the same direction in an S-shaped configuration. In another embodiment, illustrated in Fig. 6, the wings of the cylinder of tissue on the unexpanded stent are folded about stent in opposite directions in a U-shaped configuration. However, the cylinder of tissue may be placed about the unexpanded stent in a variety of suitable configurations, as for example, where the wings of the cylinder of tissue are collapsed toward the stent, such as in an accordion type configuration (not shown). It would be apparent to one of skill in the art that the heterologous tissue forming the jacket could be folded about the unexpanded stent as outlined above whether or not the tissue had been formed into a cylinder of tissue before mounting onto the unexpanded stent.

In another embodiment, the heterologous tissue is wrapped around the unexpanded stent, so that sufficient tissue to cover the expanded stent is provided. In one embodiment, illustrated in Fig. 7, a ribbon of tissue is spirally wrapped around the unexpanded stent down a length thereof. The adjacent  
5 turns of the ribbon of tissue overlap, so that the ribbon unwraps as the stent expands to provide the jacket 14 configured to cover the expanded stent and having a circumference about equal to the circumference of the expanded stent. Preferably, the ribbon of tissue is wrapped along the entire length of the stent. In another embodiment, a rectangle of tissue having a width about equal to the  
10 circumference of the expanded stent on which it is to be mounted is repeatably wrapped around the outer circumference of the unexpanded stent, so that multiple layers of tissue are present on at least a part of the unexpanded stent, as shown in Fig. 8, illustrating a transverse cross section of an unexpanded stent with a wrapped jacket thereon. Preferably, one end of the tissue is fixed  
15 to the stent, and the tissue is then tightly wrapped around the stent. Upon expansion of the stent, the tissue unwraps to provide the jacket 14 having a circumference about equal to the circumference of the expanded stent. Preferably the length of the tissue is about equal to the length of the stent.

The tissue can be caused to remain in the folded or wrapped  
20 configurations until the stent is expanded by pressing the fluid out of the folded or wrapped tissue. Additionally, securing members such as surgical tape, ties, or breakable bands may be provided to releasably hold the tissue in the folded or wrapped configurations.

Depending upon the jacket material, the tissue may be kept wet at all  
25 times during manipulation or it may be dry until advanced into the patient's blood stream. Additionally, radio-opaque markers, such as rings of gold or platinum, may be added to the outer layer of the tissue so that the integrity of the cylinder may be assured before deployment within the body lumen. The cylinder of heterologous tissue configured to be mounted onto a stent and the  
30 jacket 14 formed by the cylinder of tissue or the unwrapped or unfolded tissue generally has a length, for coronary applications, of about 4 to greater than about 80 mm, typically about 5 to about 80 mm, preferably about 10 to about

50 mm, and a diameter of about 1.5 to about 35 mm, typically about 2 to about 6 mm, preferably about 2.5 to about 5 mm. The actual length and diameter of the cylinder of heterologous tissue may vary, and will depend on the nature of the vessel in which the stent assembly is implanted. For example, for peripheral  
5 vessel applications, such as an aortic abdominal aneurysm, a larger cylinder of heterologous tissue having a length of about 5 mm to about 200 mm and a diameter of about 2 mm to about 60 mm would be used.

The jacketed stent assembly 10 is inserted into the body lumen in the following fashion. A guidewire 20 is backloaded into a delivery catheter 22  
10 having the jacketed stent assembly 10 mounted over an inflatable balloon 24 on the distal extremity of the delivery catheter (as schematically shown in Fig. 2) or on a self expanding stent delivery system (not shown). The catheter 22 and guidewire 20 are percutaneously introduced by means of a conventional Seldinger technique and a 5-9 or 10 French guiding catheter (not shown) into  
15 the patient's arterial system. Larger guiding catheters, for example up to about 25 Fr, may be used depending on the application. The guidewire 20 is advanced out delivery catheter 22 through the vasculature under fluoroscopic imaging until it crosses a stenotic region. Then the catheter 22 is advanced over the guidewire 20 until the stent assembly 10 is positioned at the desired location  
20 within the stenotic region. Then, the balloon 24 is inflated or the securing mechanism of the self expanding stent is released to expand the stent 12 and cylindrical jacket 14, seating the assembly 10 within the vessel. The balloon 24 is then deflated and the catheter 22 is removed, leaving the expanded stent assembly 10 in place.

25 Although primarily described with respect to preventing restenosis in angioplasty patients, the covered stents of this invention may be used in a number of coronary artery, peripheral artery and non-vascular applications. For example, coronary artery applications include use in ectatic arteries and ectatic arteries containing an obstructive lesion, aneurismatic arteries, saphenous vein  
30 grafts and native arteries, coronary perforation, coronary fistula, and ostial coronary lesions. Peripheral artery applications include aortic abdominal aneurysm and other aneurismatic peripheral arteries, transjugular intrahepatic

portal shunt, percutaneous transluminal angioplasty, fistula closing and neuro interventions (such as aneurysms and arterial-venous malformations), small vessel intraluminal grafting, and ostial renal artery lesions. Finally, the covered stents of this invention may be used in urological, gastroenterological, respiratory, neurological, and other non-vascular applications. For example, urological field applications include urethral stenting for stenosis due to tumors, fibrous tissue and perforation. Gastroenterological field applications include fistula closing, reconstruction such as esophagus reconstruction, and esophageal bleeding. Respiratory field applications include tracheal and bronchial obstructions, and neurological field applications include carotid angioplasty.

A general description of the device of the present invention as well as a preferred embodiment of the present invention has been set forth above. One skilled in the art will recognize and be able to practice many changes in many aspects of the device described above, including variations that fall within the teachings of this invention. For example, the assembly may include a second expandable stent, so that the heterologous tissue layer is between two coaxially disposed stents. Additionally, the jacket may cover the entire stent or only a portion thereof. Additionally, the stent assembly may be used in branched body lumens, and positioned to block one or more of the branch lumens. The spirit and scope of the invention should be limited only as set forth in the claims which follow.

**WHAT IS CLAIMED IS:**

1. A stent assembly for maintaining the patency of a body lumen comprising an expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic material.
- 5 2. The stent assembly of claim 1 wherein the cylindrical jacket is formed of heterologous tissue.
3. The stent of claim 2, wherein the heterologous tissue is selected from the group consisting of bovine pericardium, porcine pericardium, and aortic leaflet, veins and arteries.
- 10 4. The stent of claim 3, wherein the heterologous tissue comprises bovine pericardium with cross-linked collagen.
5. The stent of claim 2 including at least one therapeutic or diagnostic agent releasably contained in the cylindrical jacket.
6. The stent assembly of claim 1 wherein the material is  
15 expandable.
7. The stent assembly of claim 1 wherein the stent comprises a metallic tubular member.
8. The stent assembly of claim 1 wherein the cylindrical jacket is on an exterior surface of the stent.
- 20 9. The stent assembly of claim 1 wherein the stent is disposed within the cylindrical jacket.
10. A method for maintaining the patency of a body lumen comprising the steps of:
  - a) mounting on a delivery catheter a stent assembly  
25 comprising a tubular expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material;

- b) advancing the delivery catheter through the body lumen until the stent assembly is positioned at a desired location;
- c) expanding the stent assembly to anchor it within the bodily lumen; and
- 5 d) withdrawing the delivery catheter.

11. A cylindrical jacket formed of heterologous tissue configured to fit over a portion of an intraluminal stent.

12. The cylindrical jacket of claim 11 having a length of about 4 to about 200 mm.

10 13. The cylindrical jacket of claim 11 having a length of about 10 to about 50 mm.

14. The cylindrical jacket of claim 11 having a diameter of about 1.5 to about 60 mm.

15 15. The cylindrical jacket of claim 14 having a diameter of not greater than about 6 mm.

16. The cylindrical jacket of claim 11 having a diameter of about 2.5 to about 5 mm.

17. The cylindrical jacket of claim 11 having a thickness of about 0.05 mm to about 0.20 mm.

20 18. The cylindrical jacket of claim 11 having a thickness of about 0.1 mm to about 0.15 mm.

19. The cylindrical jacket of claim 11 configured to fit over an outer portion of the intraluminal stent.

25 20. The cylindrical jacket of claim 11 configured to cover an inner portion of the intraluminal stent.

21. A method of treating a patient, comprising:

- a) providing an elongated delivery catheter having an expandable member on a distal extremity thereof;
- b) mounting an expandable stent having a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material onto the expandable member on the distal extremity of the delivery catheter;
- c) advancing at least the distal extremity of the catheter within a body lumen of the patient until the jacketed stent is disposed at a desired location within the body lumen;
- d) expanding the expandable member on the distal extremity of the catheter to expand the jacketed stent mounted thereon and fix the expanded jacketed stent within the body lumen; and
- e) contracting the expanded expandable member so the elongated delivery catheter can be removed from the patient.

22. A stent assembly for maintaining the patency of a body lumen comprising an expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material containing a therapeutic or diagnostic agent.

23. The stent assembly of claim 22 wherein the therapeutic agent is selected from the group consisting of antithrombotic agents and angiogenesis agents.

24. The stent assembly of claim 23 wherein the antithrombotic agent is selected from the group consisting of is selected from the group consisting of heparin, urokinase, streptokinase, tissue plasminogen activator, and abciximab, and the angiogenesis agent is selected from the group consisting of Fibroblast Growth Factor and Vascular Endothelial Growth Factor.



25. The stent assembly of claim 22 wherein material comprises heterologous tissue configured to fit over at least one of an outer surface and an inner surface of the stent.

26. A method for maintaining the patency of a body lumen  
5 comprising the steps of:

- a) mounting on a delivery catheter a stent assembly comprising a tubular expandable stent with a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material containing a therapeutic or diagnostic agent;
- 10 b) advancing the delivery catheter through the body lumen until the stent assembly is positioned at a desired location;
- c) expanding the stent assembly to anchor it within the bodily lumen and deliver the therapeutic or diagnostic agent to the desired location within the body lumen; and
- 15 d) withdrawing the delivery catheter.

27. The method of claim 26 wherein the delivery catheter has an expandable member on a distal extremity thereof, and including the step of mounting the expandable stent onto the delivery catheter expandable member, and wherein the step of expanding the stent comprises  
20 expanding the delivery catheter expandable member.

28. The method of claim 26 including the step of contracting the expanded expandable member so the delivery catheter can be removed from the patient.

29. An expandable jacketed stent comprising a metallic tubular  
25 member configured to expand from a first circumference configuration to a second circumference configuration, and a jacket formed of heterologous tissue containing a therapeutic or diagnostic agent and having a thickness of about 0.05 mm to about 0.20 mm.

30. The jacketed stent of claim 29 wherein the jacket is on an outer surface of the stent in a folded configuration configured to unfold as the stent expands to the second circumference configuration.

5 31. The jacketed stent of claim 29 wherein the jacket is on an outer surface of the stent in a wrapped configuration configured to unwrap as the stent expands to the second circumference configuration.

32. A method of treating a patient, comprising:

- 10 a) providing an elongated delivery catheter having an expandable member on a distal extremity thereof;
- b) mounting onto the expandable member on the distal extremity of the delivery catheter an expandable stent having first circumference and a second expanded circumference and having a cylindrical jacket formed of biocompatible, non-thrombogenic expandable material on an outer surface of the stent, the jacket  
15 having a width about equal to the second expanded circumference of the stent;
- c) advancing at least the distal extremity of the catheter within a body lumen of the patient until the jacketed stent is disposed at a desired location within the body lumen;
- 20 d) expanding the expandable member on the distal extremity of the catheter to expand the jacketed stent mounted thereon and fix the expanded jacketed stent within the body lumen; and
- e) contracting the expanded expandable member so the  
25 elongated delivery catheter can be removed from the patient.

33. The method of claim 32 wherein the jacket is in a folded configuration configured to unfold as the stent expands to the second circumference configuration.

34. The method of claim 32 wherein the jacket is in a wrapped configuration configured to unwrap as the stent expands to the second circumference configuration.




FIG. 1




FIG. 3




FIG. 2

FIG. 4




FIG. 6




FIG. 5




FIG. 7





FIG. 8



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01459

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 09006 A (UNIV EMORY) 13 March 1997	1-9, 11, 19, 20, 22-25
A	see page 5, line 7 - line 13  see page 6, paragraph 2 see page 7, paragraph 2 - paragraph 3 see figure 4A see claims 1,2  --- -/--	12, 14, 15, 17, 18, 29-31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 December 1998

Date of mailing of the international search report

05/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mary, C

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01459

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 24081 A (RAMUS MEDICAL TECHNOLOGIES ; LOVE CHARLES S (US)) 10 July 1997  see figures 3,4	1-4,6-9, 11-13, 19,20
A	see page 8, line 30 - page 10, line 27  see page 11, line 1 - line 12 see page 12, line 21 - line 36 ---	14-16, 29-31
X	US 5 575 818 A (PINCHUK LEONARD) 19 November 1996	1-9,11, 19,22
A	see column 8, line 7 - column 9, line 4 see column 6, line 64 - column 7, line 2 see figure 8B ---	8-10
X	WO 94 15583 A (PDT SYSTEMS INC) 21 July 1994 see page 9, line 9 - line 15 see page 11, line 26 - line 29 see page 12, line 8 - line 15 see claim 4 see claims 9-12 see figure 7 ---	1,2,5-9, 11,19,22
X	WO 97 12563 A (RAWLINGS MALCOLM ;ADELMAN ALLAN (CA)) 10 April 1997 see page 3, paragraph 1 see page 8, paragraph 2 see figure 1 ---	1,2,8,9, 11,19
X	US 5 556 414 A (TURI ZOLTAN G) 17 September 1996	22,23
A	see column 4, line 50 - column 5, line 41 see column 6, line 11 - line 39 see column 12, line 30 - line 45 -----	11,20



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 98/01459

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10, 21, 26-28, 32-34  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/IB 98/01459

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9709006 A	13-03-1997	AU 6905696 A EP 0853465 A	27-03-1997 22-07-1998
WO 9724081 A	10-07-1997	AU 1569297 A CA 2240989 A EP 0874603 A	28-07-1997 10-07-1997 04-11-1998
US 5575818 A	19-11-1996	EP 0812164 A WO 9625124 A	17-12-1997 22-08-1996
WO 9415583 A	21-07-1994	US 5429634 A AU 675505 B AU 6086694 A CA 2153248 A EP 0691841 A US 5419760 A	04-07-1995 06-02-1997 15-08-1994 21-07-1994 17-01-1996 30-05-1995
WO 9712563 A	10-04-1997	CA 2181522 A	04-04-1997
US 5556414 A	17-09-1996	EP 0874602 A WO 9627347 A	04-11-1998 12-09-1996




FIG. 1




FIG. 3




FIG. 2




FIG. 4




FIG. 6




FIG. 5

FIG. 7




FIG. 8

